Directors' dealings

Share this page

Directors' dealings

QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy ca be downloaded as PDF document here

  • Notes to the overview of recent transactions 

    * Cashless Exercise

    1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

    2) Manfred Karobath, Stéphane Bancel, Metin Colpan, Ross L. Levine, Elaine R. Mardis, Lawrence A. Rosen, Elizabeth E. Tallett.

    3) “Sell to cover” transaction in which only the portion of the shares vested is sold required to cover expenses related to the receipt of the shares such as taxes, transaction costs.


    a) Expiration date of underlying options due to Dr. Brandt's resignation from the Supervisory Board of QIAGEN N.V. after the Annual General Meeting: September 20, 2016.

    b) A performance-based stock program was introduced for a small group of executives in November 2013. The vesting of shares in this program, and also percentages of shares granted, will be measured on the performance of QIAGEN over several years in terms of net sales, adjusted EBIT and QVA, a value creation measurement system related to ROIC and EVA. Program replaces stock option grants over period and contingent upon a commitment to mandatory minimum share ownership.

    c) 10 year expiration date of underlying options: February 28, 2017.

    d) Represents conversion of a portion of 2016 cash bonus into Performance Stock Units.

    e) Adjustments in holdings after synthetic share repurchase completed in January 2017 (every 27 issued QIAGEN shares were consolidated into 26 QIAGEN shares and a direct capital repayment of $1.04 for each of the 27 prior-reduction shares).   

    f) 10 year expiration date of underlying options: April 25, 2017.

    g) Grant is part of a performance-based stock program for a small group of executives. The vesting of shares in this program, and also percentage of shares granted, will be measured on the performance of QIAGEN in 2017 in terms of sales, adjusted operating income and adjusted free cash flow.

    h) 10 year expiration date of underlying options: February 28, 2018.

Recent transactions

Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM
Roland Sackers,
Managing Director 
06/06/17 
Sale *h) 
Stock Options
(Expiry: February 28, 2018) 
33,638   PDF PDF PDF
Peer M. Schatz,
Managing Director 
05/05/17 
Grant g) 
Performance Stock Units  100,000 - PDF PDF
Roland Sackers,
Managing Director 
05/05/17 
Grant g) 
Performance Stock Units  100,000 - PDF PDF
Peer M. Schatz,
Managing Director
05/01/17
Sale 

Performance Common Shares received
through release of Performance Stock Units ("sell to cover")

8,760 PDF PDF PDF
Peer M. Schatz,
Managing Director
04/28/17  Common Shares received through
release of Performance Stock Units 
18,387 - PDF PDF
Manfred Karobath,
Metin Colpan,
Supervisory Director 
04/26/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")  
284 PDF PDF PDF
Manfred Karobath,
Metin Colpan,
Supervisory Director 
04/25/17  Common Shares received through 
release of Restricted Stock Units 
538 PDF PDF
Peer M. Schatz,
Managing Director 
03/29/17
Sale 
Common Shares received through 
release of Performance Stock Units 
("sell to cover") 
345,053 PDF PDF PDF
  03/28/17  Common Shares received through 
release of Performance Stock Units  
717,907 PDF PDF
Peer M. Schatz,
Managing Director
03/16/17
Sale 
Common Shares received through 
release of Performance Stock Units 
("sell to cover")  
6,079.92 PDF PDF PDF
  03/15/17  Common Shares received through 
release of Performance Stock Units  
12,454 PDF PDF
Roland Sackers,
Managing Director 
03/16- 03/17/17
Sale1 
Common Shares received through 
release of Performance Stock Units 
3,997 PDF PDF PDF
  03/15/17  Common Shares received through 
release of Performance Stock Units  
3,997 PDF PDF
Manfred Karobath,
Metin Colpan,
Supervisory Director 
03/03/17 
Sale*1)f) 
Stock Options
(Expiry: April 25, 2017) 
1,942 PDF PDF PDF
Manfred Karobath,
Supervisory Director 
03/07/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")    
3,442 PDF PDF PDF
  03/01/17  Common Shares received through 
release of Restricted Stock Units 
2,716 PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units 
4,000 PDF PDF
Metin Colpan,
Supervisory Director 
03/02/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")     
1,439 PDF PDF PDF
  03/01/17  Common Shares received through 
release of Restricted Stock Units  
2,716 PDF PDF
Metin Colpan,
Supervisory Director 
03/01/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover") 
2,119 PDF PDF PDF
  02/28/17 Common Shares received through 
release of Restricted Stock Units
4,000 PDF PDF

Elizabeth E. Tallett, Supervisory Director 

03/07/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")    
2,764 PDF PDF PDF
  03/01/17  Common Shares received through 
release of Restricted Stock Units 
2,716 PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units 
4,000 PDF PDF
Stéphane Bancel,
Supervisory Director 
03/01/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")    
1,919 PDF PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units 
4,000 PDF PDF
Lawrence A. Rosen,
Supervisory Director 
03/01- 03/02/17
Sale1) 
Common Shares received through 
release of Restricted Stock Units  
4,000 PDF PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units  
4,000 PDF PDF
Peer M. Schatz,
Managing Director 
03/02/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")   
111,456 PDF PDF PDF
  03/01/17  Common Shares received through 
release of Restricted Stock Units 
232,590 PDF PDF
Peer M. Schatz,
Managing Director 
03/01/17
Sale 
Common Shares received through 
release of Restricted Stock Units
("sell to cover")    
88,849 PDF PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units  
185,204 PDF
PDF
Roland Sackers,
Managing Director  
03/02/17
Sale1) 
Common Shares received through 
release of Restricted Stock Units  
77,950 PDF PDF PDF
  03/01/17  Common Shares received through 
release of Restricted Stock Units  
77,950 PDF PDF
Roland Sackers,
Managing Director  
03/01- 03/02/17
Sale1) 
Common Shares received through 
release of Restricted Stock Units  
46,537 PDF PDF PDF
  02/28/17  Common Shares received through 
release of Restricted Stock Units  
46,537 PDF PDF
All Supervisory Board Directors 2)  02/28/17 
Grant 
Restricted Stock Units  10,732 PDF PDF
Peer M. Schatz,
Managing Director  
02/28/17 
Grant 
Performance Stock Units  345,000 PDF PDF
Roland Sackers,
Managing Director  
02/28/17 
Grant 
Performance Stock Units  86,075 PDF PDF
Peer M. Schatz,
Managing Director   
02/16/17
Sale 
Common Shares received through 
release of Restricted and Performance
Stock Units
 ("sell to cover")
22,123 PDF  PDF PDF
Peer M. Schatz,
Managing Director   
02/15/17  Common Shares received through 
release of Restricted and Performance
Stock Units
 
47,357 PDF PDF
Roland Sackers,
Managing Director  
02/16/17
Sale1) 
Common Shares received through 
release of Restricted and Performance
Stock Units
 
15,160 PDF PDF PDF
Roland Sackers,
Managing Director  
02/15/17  Common Shares received through 
release of Restricted and Performance
Stock Units
 
15,160 PDF PDF
Manfred Karobath,
Supervisory Director 
01/25/17 Common Shares
(Adjustment in Holdinge
692 PDF PDF
Metin Colpan,
Supervisory Director 
01/25/17  Common Shares
(Adjustment in Holdinge 
135,519 PDF PDF
Elizabeth E. Tallett,
Supervisory Director 
01/25/17  Common Shares
(Adjustment in Holdinge 
187 PDF PDF
Peer M. Schatz,
Managing Director   
01/25/17  Common Shares
(Adjustment in Holdinge 
78,842.08 PDF PDF
Roland Sackers,
Managing Director  
01/25/17  Common Shares
(Adjustment in Holdinge 
742 PDF PDF
Roland Sackers,
Managing Director  
12/16/16
Grantd) 
Performance Stock Units  23,419 PDF PDF
Roland Sackers,
Managing Director  
12/01/16
Sale1) 
Common Shares received through 
release of Restricted Stock Units   
9,729 PDF PDF PDF
Roland Sackers,
Managing Director  
11/30/16   Common Shares received through 
release of Restricted Stock Units   
9,729 PDF PDF
Peer Schatz,
Managing Director 
11/25 - 11/28/16 
Sale *1)c) 
Stock Options
(Expiry: Februar 28, 2017) 
114,551 PDF PDF PDF
Peer Schatz
Managing Director 
10/31/16
Grantb) 
Performance Stock Units  460,220 PDF PDF
Roland Sackers,
Managing Director   
10/31/16
Grantb) 
Performance Stock Units 144,809 PDF PDF
SOCIAL SHARING